Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...

Ozempic is ubiquitous, but it wasn't always this way. The new trend was explored on the latest "Well with Arielle Lorre." ...